{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021665","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.417619+00:00","generated_at":"2026-06-02T10:33:13.547167+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete","bullets":["Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.","Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.","VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.","VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.","Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021665","json":"https://secwatch.observer/filing/0001628280-24-021665.json","markdown":"https://secwatch.observer/filing/0001628280-24-021665.md","text":"https://secwatch.observer/filing/0001628280-24-021665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/0001628280-24-021665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/pcvx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:33:13.547167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3973cbd286638624447f64c8d3dc00c820b8b019","claim":"Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000162828024021665/0001628280-24-021665-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}